Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Halozyme Therapeutics, Inc. (HALO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company, Halozyme uses Forms 10-K, 10-Q and 8-K to report on its drug delivery business, collaborations, financing activities and governance matters.
Through current reports on Form 8-K, Halozyme discloses material events such as the issuance of convertible senior notes due 2031 and 2032, amendments to its revolving credit facility, entry into and completion of the Elektrofi acquisition, significant collaboration agreements, and executive appointments or transitions. These filings often include details on note terms, capped call transactions, credit covenants and merger conditions that are not fully described in press releases.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (not reproduced here but referenced in 8-Ks) typically contain broader discussions of Halozyme’s ENHANZE, Hypercon and MDASE technology portfolios, risk factors, royalty and collaboration structures, and overall financial condition. Investors use these filings to understand how platform licensing, proprietary products and acquisitions contribute to the company’s long-term strategy.
Stock Titan enhances this information with AI-powered summaries that highlight key terms in lengthy documents, such as conversion conditions for the company’s notes, leverage and coverage ratios in its credit agreement, and the main obligations and covenants in merger contracts. Users can also review disclosures related to executive compensation arrangements, transition agreements and other governance topics reported under Item 5.02 of Form 8-K.
By combining real-time updates from EDGAR with AI-generated explanations, the Halozyme filings page helps readers quickly locate and interpret the sections of 10-Ks, 10-Qs, 8-Ks and related exhibits that are most relevant to their analysis of HALO stock.
Halozyme Therapeutics SVP and Chief Legal Officer Mark Howard Snyder reported multiple equity compensation events. On February 20 and 23, 2026, restricted stock units vested and were settled into 5,332 and 7,011 shares of common stock, respectively, through derivative exercises at $0.00 per share.
To satisfy tax withholding obligations, the issuer withheld 2,876 shares at $70.98 and 3,782 shares at $70.64, recorded as tax-withholding dispositions rather than open-market sales. After these transactions, Snyder directly owned 47,610 shares of Halozyme common stock.
Halozyme Therapeutics SVP & CFO Nicole LaBrosse reported equity award vesting and related tax-withholding transactions. On February 23, 6,688 Performance Stock Units were exercised into 6,688 shares of common stock, and 3,608 shares were withheld at $70.64 per share to cover taxes. On February 20, 5,332 Restricted Stock Units vested into 5,332 common shares, with 2,876 shares withheld at $70.98 per share for tax obligations. After these transactions, she directly held 38,494 shares of common stock, 36,357 Performance Stock Units, and 15,995 Restricted Stock Units.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported equity compensation activity involving restricted stock units and related common stock. On February 20 and 23, 2026, restricted stock units vested and were settled into a total of 22436 and 16757 shares of common stock through derivative exercises.
On both dates, a portion of the newly delivered common shares, 9040 and 12104 shares respectively, was automatically withheld by the issuer to cover tax withholding obligations at prices of $70.98 and $70.64 per share, rather than sold in open‑market transactions. After these transactions, Torley directly owned 767780 shares of common stock and 44872 restricted stock units.
Snyder Mark Howard reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 42,692 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 4,796 shares.
LaBrosse Nicole reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 60,440 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 5,329 shares.
Torley Helen reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 226,153 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 16,874 shares.
Halozyme Therapeutics, Inc. presents an annual overview of its business focused on drug-delivery technologies that convert intravenous therapies to subcutaneous injections. The company’s ENHANZE platform, based on its rHuPH20 enzyme, is widely licensed to major biopharma partners, generating upfront fees, milestones, bulk enzyme sales and royalties from ten commercial products.
Halozyme also develops Hypercon and Surf Bio hyperconcentration technologies and pressure-assisted auto-injectors, plus proprietary products Hylenex and XYOSTED. It highlights extensive global partnerships with Roche, Takeda, Janssen, argenx, BMS and others, alongside detailed risk factors spanning regulatory approval, supply chain, competition, financing, cybersecurity and market volatility.
Halozyme Therapeutics reported another year of strong top-line growth in 2025, with total revenue of $1.3966 billion, up 38% from 2024. Royalty revenue rose 52% to a record $867.8 million, driven mainly by ENHANZE-enabled products such as VYVGART Hytrulo, DARZALEX SC and Phesgo.
Despite this, full-year net income declined to $316.9 million from $444.1 million, as results absorbed $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition and higher operating costs. The company posted a fourth-quarter net loss of $141.6 million after these charges.
Halozyme expanded its drug-delivery portfolio by acquiring Elektrofi and Surf Bio and completed $1.5 billion of new convertible notes while increasing its revolving credit facility to $750 million. For 2026, it reiterates guidance for total revenue of $1.710–$1.810 billion, adjusted EBITDA of $1.125–$1.205 billion and non-GAAP diluted EPS of $7.75–$8.25, all implying robust double-digit growth over 2025.
Halozyme Therapeutics executive Cortney Caudill received new equity awards under the company’s compensation programs. On 02/09/2026, the SVP and Chief Operating Officer acquired an option to purchase 14,047 shares of common stock at $80.48 per share, vesting over four years starting 02/09/2027.
Caudill was also granted 13,047 restricted stock units that vest 25% on the first anniversary of the grant date and 25% on each anniversary thereafter. In addition, performance stock units tied to performance periods ending December 31, 2025 became eligible to vest, covering 2,403 and 14,751 shares, subject to continued service through the third anniversary of their original PSU grant dates.
Halozyme Therapeutics reported that SVP and Chief Legal Officer Mark Howard Snyder received several equity awards on February 9, 2026. He was granted an option to purchase 18,730 shares of common stock at an exercise price of $80.48, vesting one-fourth on the grant date and then monthly in equal installments.
He was also awarded 17,396 restricted stock units that vest in four equal annual installments starting one year after the grant, plus multiple performance stock unit awards. Performance stock units of 4,651, 7,808, and 29,502 shares became eligible to vest based on a performance period ending December 31, 2025 and remain subject to additional service-based vesting through the third anniversary of each original PSU grant date.